Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.37 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | WNT1 | P04628 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6630471 | 0.83 | ALDH1A1 (0.48) | ALDH1A1KDM4EKCNJ1TDP1MAPT | |
| SCHEMBL7230926 | 0.79 | ALDH1A1 (0.57) | ALDH1A1KDM4EKCNJ1TDP1MAPT | |
| SCHEMBL13091412 | 0.74 | TMPRSS15 (0.34) | ALDH1A1KDM4EMAPTLMNAWNT1 | |
| SCHEMBL15827106 | 0.72 | CNR1 (0.45) | ALDH1A1TDP1LMNA | |
| SCHEMBL2411773 | 0.72 | ALDH1A1 (0.41) | ALDH1A1KDM4EKCNJ1TDP1 | |
| SCHEMBL20284239 | 0.71 | ALDH1A1 (0.50) | ALDH1A1KDM4EKCNJ1TDP1MAPT | |
| SCHEMBL15889359 | 0.71 | — | — | |
| SCHEMBL26365042 | 0.71 | GBA1 (0.33) | ALDH1A1 | |
| SCHEMBL27748773 | 0.71 | TDP1 (0.34) | ALDH1A1KDM4ETDP1 | |
| SCHEMBL13349426 | 0.71 | FDPS (0.37) | ALDH1A1TDP1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9815849-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815849-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20040220188-A1 | Alkylidene pyrazolidinedione derivatives | LABORATOIRES SERONO SA (CH) | 2004-11-04 | — | — | US | disclosed |
| EP-1399156-A2 | ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY | Applied Research Systems ARS Holding N.V. (AN) | 2004-03-24 | — | — | EP | disclosed |
| WO-2004016611-A1 | USE OF AND SOME NOVEL IMIDAZOPYRIDINES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
| WO-2002102359-A2 | ALKYLIDENE PYRAZOLIDINEDIONE DERIVATIVES AND USE FOR TREATING DIABETES AND OBESITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-12-27 | — | — | WO | disclosed |
| EP-0453395-B1 | Pressure sensitive recording material | CIBA GEIGY AG (CH) | 1995-11-02 | — | — | EP | disclosed |
| US-5254522-A | Pressure-sensitive or heat-sensitive recording material | CIBA-GEIGY CORPORATION (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0453395-A1 | Pressure sensitive recording material | CIBA-GEIGY AG (CH) | 1991-10-23 | — | — | EP | disclosed |
| US-4002616-A | POLYESTERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-01-11 | — | — | US | disclosed |
| US-3962220-A | ONE-STEP, AROMATIC ALDEHYDES, ACETIC ACID | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
| US-3962221-A | CONDENSATION, REDUCTION, OXIDATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | ALDH1A1 2424/4885KDM4E 1552/4885KCNJ1 4817/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | ALDH1A1 3670/4885KDM4E 317/4885KCNJ1 3997/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | ALDH1A1 1723/4885KDM4E 1909/4885KCNJ1 2658/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | ALDH1A1 2424/4885KDM4E 1552/4885KCNJ1 4817/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | ALDH1A1 1723/4885KDM4E 1909/4885KCNJ1 2658/4885 |
| US-20040220188-A1 | Alkylidene pyrazolidinedione derivatives | G6PC1, PPM1D, PTPRS | ALDH1A1 721/4885KDM4E 3027/4885KCNJ1 1776/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | ALDH1A1 3670/4885KDM4E 317/4885KCNJ1 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.